Proteomics

Dataset Information

66

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 AML Cells


ABSTRACT: Constitutively activating internal tandem duplication (ITD) alterations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) are common in acute myeloid leukemia (AML) and classifies FLT3 as an attractive therapeutic target. So far, application of FLT3 small molecule inhibitors such as Sorafenib has resulted only in partial and transient clinical responses in FLT3-ITD+ patients. Only recently, a prolonged event-free survival has been observed in AML patients who were treated with Sorafenib in addition to standard therapy. Here, we studied the Sorafenib effect on proliferation in a panel of 13 FLT3-ITD- and FLT3-ITD+ AML cell lines. Sorafenib IC50 values ranged from 0.001 to 5.6 µM, whereas FLT3-ITD+ cells (MOLM-13, MV4;11) were found more sensitive to Sorafenib than FLT3-ITD- cells. However, we identified two FLT3-ITD- cell lines (MONO-MAC-1 and OCI-AML-2) which were also Sorafenib sensitive. Phosphoproteome analyses revealed that the affected pathways differed in Sorafenib sensitive FLT3-ITD- and FLT3-ITD+ cells. In MV4;11 cells Sorafenib suppressed mTOR signalling by inhibiting direct inhibition of FLT3. In MONO-MAC-1 cells Sorafenib inhibited the MEK/ERK pathway by inhibition of the RET tyrosine kinase. These data suggest that the FLT3 status in AML patients might not be the only predictive factor for a response to Sorafenib.

INSTRUMENT(S): LTQ Orbitrap Velos

ORGANISM(S): Homo sapiens  

TISSUE(S): Cell Culture

DISEASE(S): Acute Leukemia

SUBMITTER: Christoph Schaab  

LAB HEAD: Christoph Schaab

PROVIDER: PXD004442 | Pride | 2017-05-02

REPOSITORIES: Pride

altmetric image

Publications

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.

Roolf Catrin C   Dybowski Nikolaj N   Sekora Anett A   Mueller Stefan S   Knuebel Gudrun G   Tebbe Andreas A   Murua Escobar Hugo H   Godl Klaus K   Junghanss Christian C   Schaab Christoph C  

Molecular & cellular proteomics : MCP 20170427 7


Constitutively activating internal tandem duplication (ITD) alterations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) are common in acute myeloid leukemia (AML) and classifies FLT3 as an attractive therapeutic target. So far, applications of FLT3 small molecule inhibitors have been investigated primarily in FLT3-ITD+ patients. Only recently, a prolonged event-free survival has been observed in AML patients who were treated with the multikinase inhibitor sorafenib in addition  ...[more]

Similar Datasets

2018-02-01 | E-MTAB-4487 | ArrayExpress
| GSE95770 | GEO
2016-03-02 | E-MTAB-4487 | ExpressionAtlas
2012-02-18 | E-GEOD-35907 | ArrayExpress
| GSE104594 | GEO
2017-05-10 | PXD006475 | Pride
2020-03-02 | PXD015639 | Pride
2010-04-08 | E-GEOD-12766 | ArrayExpress
2016-08-01 | E-GEOD-74666 | ArrayExpress
2010-07-30 | E-GEOD-18018 | ArrayExpress